ViroMissile has isolated a strain of Vaccinia virus that survives in blood – unlike any other virus in development – to deliver proprietary immune activating signals to battle cancer.
Our Vision
Defeating cancer with a smarter virus.
Developing the world’s first truly intravenously-delivered viruses that target and kill tumors.
”ViroMissile is the first company to achieve successful and effective intravenous delivery of an oncolytic virus directly to tumors in humans.
Dr. Nanhai George ChenChief Executive Officer, ViroMissile
Science
We leverage a unique strain of the vaccinia virus to trigger the immune system to destroy tumors
Vaccinia virus preferentially infects cancer cells while sparing healthy cells. Our proprietary strain survives in the bloodstream, enabling systemic administration to reach tumors throughout the body. Once inside the tumor, the virus can hijack the cancer cell machinery to turn the tumor into anti-cancer treatment factories. With its large payload capacity, we’re able to send in many different types of instructions to promote anti-tumor activity.
Precision Targeting
Our smart virus technology navigates the bloodstream to find and infiltrate tumor cells with missile-like accuracy, regardless of tumor location or type.
Patient-Centered Design
Our approach concentrates therapeutic action at tumor sites, aiming to reduce side effects compared to conventional therapies.
Pipeline
Proven proof-of-concept: IDOV-Safe
First-in-human systemic delivery of oncolytic virus with adaptable payloads
We have genetically modified our platform virus to create candidates with 4 unique features for distinct anti-tumor effects. We seek to evaluate these, along with combinations and additional features, in future generations of our platform.
Traditional drug development faces limitations
The paradigm of cancer therapy is shifting. Years of research and hundreds of millions of dollars are spent on developing a treatment that often targets one driver of one cancer type.
Our IDOV Platform seeks to deliver customized anti-cancer payloads to a broader range of tumors with greater effect
To be effective against metastatic disease, therapies need to reach every tumor in the body – regardless of how they are administered. Our IDOV Platform allows for systemic administration of precision anti-cancer compounds that are delivered where they are needed, eliminating systemic side effects while maximizing therapeutic impact.
Awarded "Top Cancer Destroying Platform" (2025) by Life Sciences Review
Read the Life Sciences Review profile on ViroMissile and CEO, Dr. Nanhai George Chen.